Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole

INTRODUCTION: Clinical resistance is a major factor limiting benefits to endocrine therapy. Causes of resistance may be diverse and the mechanism of resistance in individual breast cancers is usually unknown. The present study illustrates how changes in the expression of proliferation and oestrogen-...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, William R, Larionov, Alexey
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949641/
https://www.ncbi.nlm.nih.gov/pubmed/20646288
http://dx.doi.org/10.1186/bcr2611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949641/
https://www.ncbi.nlm.nih.gov/pubmed/20646288
http://dx.doi.org/10.1186/bcr2611

Ejemplares similares